Brief: BB Biotech Q1 Net Result Turns To Loss Of CHF 300 Mln

Bb Biotech

22/04/2022 06:12

April 22 (Reuters) - BB BIOTECH AG  BION.S :
    * INCREASED INVESTMENT LEVEL BALANCED BY ESTABLISHED CORE
HOLDINGS
    * INCREASED INVESTMENT LEVEL BALANCED BY ESTABLISHED CORE
HOLDINGS
    * FOR Q1 2022, BB BIOTECH SHARES' TOTAL RETURN WAS -11.3% IN
CHF
AND -8.6% IN EUR
    * FOR Q1 2022, SHARES TOTAL RETURN WAS -11.3% IN CHF AND
-8.6% IN
EUR
    * PAID OUT PROPOSED DIVIDEND OF CHF 3.85 PER SHARE
    * FY CONSEQUENTLY, NET LOSS FOR Q1 OF 2022 WAS CHF 300 MN
COMPARED
TO A NET GAIN OF CHF 221 MN FOR SAME PERIOD IN 2021
    * BY END OF Q1, INVESTMENT LEVEL AT 113.0% WAS SLIGHTLY
HIGHER
THAN 110.9% AT BEGINNING OF YEAR

Source text for Eikon:  ID:nEQ585zQHa 
Further company coverage:  BION.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))